Editas Medicine (EDIT) Net Income towards Common Stockholders (2015 - 2025)
Editas Medicine (EDIT) reported Net Income towards Common Stockholders of -$25.1 million for Q3 2025, up 59.58% year-over-year from -$15.7 million in Q3 2024, and up 51.21% quarter-over-quarter from -$51.5 million in Q2 2025.
Editas Medicine (EDIT) Net Income towards Common Stockholders (2015 - 2025) Analysis & Trends
Editas Medicine (EDIT) has 11 years of Net Income towards Common Stockholders data on file, last reported at -$25.1 million in Q3 2025.
- Net Income towards Common Stockholders for Q3 2025 came in at -$25.1 million, up 59.58% year-over-year; the trailing twelve-month figure through Dec 2025 was -$152.3 million (up 35.78% YoY), and the FY2024 annual result was -$237.1 million, down 56.38% from the prior year.
- Net Income towards Common Stockholders advanced to -$25.1 million in Q3 2025 per EDIT's latest filing, from -$51.5 million in the prior quarter.
- Over five years, Net Income towards Common Stockholders peaked at -$18.9 million in Q4 2023 and troughed at -$75.7 million in Q1 2025.
- A 5-year average of -$50.2 million and a median of -$51.5 million in 2025 frame the typical range for Net Income towards Common Stockholders.
- The sharpest annual moves came in 2021 and 2023: Net Income towards Common Stockholders sank 600.08% in 2021, then jumped 68.95% in 2023.
- A 5-year view of Net Income towards Common Stockholders shows it stood at -$41.4 million in 2021, then slumped by 46.58% to -$60.7 million in 2022, then jumped by 68.95% to -$18.9 million in 2023, then slumped by 140.68% to -$45.4 million in 2024, then jumped by 44.67% to -$25.1 million in 2025.
- Business Quant data shows EDIT's Net Income towards Common Stockholders at -$25.1 million in Q3 2025, -$51.5 million in Q2 2025, and -$75.7 million in Q1 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Net Income (Qtr) |
|---|---|---|---|---|---|
| 1 | Alterity Therapeutics | 925,601.88 Bn | 925,601.85 Bn | - | - |
| 2 | Belite Bio | 58,560.00 Bn | 58,560.00 Bn | - | -26.94 Mn |
| 3 | Quantum Biopharma | 17,284.41 Bn | 17,284.40 Bn | - | -13.56 Mn |
| 4 | Legend Biotech | 2,809.00 Bn | 2,808.71 Bn | 242.10 Mn | 2.50 Mn |
| 5 | Evaxion A | 1,334.43 Bn | 1,334.42 Bn | - | -3.63 Mn |
| 6 | Akari Therapeutics | 1,312.27 Bn | 1,312.26 Bn | - | -14.46 Mn |
| 7 | Psyence Biomedical | 212.16 Bn | 212.16 Bn | - | -1.50 Mn |
| 8 | Vertex Pharmaceuticals | 114.83 Bn | 107.58 Bn | 2.59 Bn | 1.03 Bn |
| 9 | Abivax | 91.96 Bn | 91.96 Bn | - | -56.48 Mn |
| 10 | Editas Medicine | 262.77 Mn | 262.77 Mn | - | - |
Historic Data
Download Data| Date | Value |
|---|---|
| Sep 30, 2025 | -25.12 Mn |
| Jun 30, 2025 | -51.48 Mn |
| Mar 31, 2025 | -75.66 Mn |
| Dec 31, 2024 | -45.39 Mn |
| Sep 30, 2024 | -62.14 Mn |
| Jun 30, 2024 | -67.61 Mn |
| Mar 31, 2024 | -61.96 Mn |
| Dec 31, 2023 | -18.86 Mn |
| Sep 30, 2023 | -45.02 Mn |
| Jun 30, 2023 | -40.28 Mn |
| Mar 31, 2023 | -47.45 Mn |
| Dec 31, 2022 | -60.73 Mn |
| Sep 30, 2022 | -55.73 Mn |
| Jun 30, 2022 | -53.69 Mn |
| Mar 31, 2022 | -50.28 Mn |
| Dec 31, 2021 | -41.44 Mn |
| Sep 30, 2021 | -39.10 Mn |
| Jun 30, 2021 | -55.26 Mn |
| Mar 31, 2021 | -56.75 Mn |
| Dec 31, 2020 | -62.50 Mn |